What's Going On With Marker Therapeutics (MRKR) Stock

Marker Therapeutics, Inc. MRKR shares are trading higher by 3.0% to $5.50 Tuesday morning. The stock is rising on continued momentum after the company on Monday announced the European Medicines Agency granted MT-401 an Orphan Drug Designation.

What Else?

The drug is for the treatment of patients with acute myeloid leukemia (AML). Per Marker, AML is a life-threatening disease with high relapse rates and poor outcomes after hematopoietic stem cell transplant (HSCT).

MT-401 is designed to target multiple tumor-associated antigens and is currently being evaluated in a Phase 2 clinical trial for relapsed AML post-HSCT. Orphan Drug Designation provides regulatory support, including market exclusivity, reduced fees and scientific advice from the EMA.

See Also: Why BioRestorative Therapies (BRTX) Stock Is Getting Hammered

Marker Therapeutics meanwhile says the company is committed to advancing MT-401 development and approval to address the significant unmet needs in AML treatment.

According to data from Benzinga Pro, MRKR has a 52-week high of $6.60 and a 52-week low of $$0.67.